Peking University: Esophageal Squamous Cell Carcinoma trials

The registry lists 20 Esophageal Squamous Cell Carcinoma studies with Peking University as lead sponsor. 4 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 3Phase 2 15Phase 3 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell CarcinomaEnrolling by invitationNCT07312578Phase 2
• Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell CarcinomaRecruitingNCT06690476Early Phase 1
• Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06684600Phase 2
• To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCCRecruitingNCT05818982Phase 2
• Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT05386056Phase 2
• JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard TherapyStatus unknownNCT05164848Phase 1
• The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaStatus unknownNCT04937673Phase 2
• Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR AmplificationStatus unknownNCT04880811Phase 2
• Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell CarcinomaTerminatedNCT04804696Phase 2
• Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular CharacteristicsActive, not recruitingNCT04584008Not applicable
• Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)Status unknownNCT03940976Phase 2
• Metformin in Combined With Cisplatin Plus Paclitaxel With Advanced Esophageal Squamous Cell Carcinoma (ECMTPneo)Status unknownNCT03833466Phase 2
• Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell CarcinomaTerminatedNCT03251417Phase 2
• Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT03126708Phase 2
• Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell CarcinomaCompletedNCT02645864Phase 1
• Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell CarcinomaWithdrawnNCT02272699Phase 2/3
• Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.Status unknownNCT01993784Phase 1/2
• Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC)Active, not recruitingNCT01688908Not applicable
• Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell CancerStatus unknownNCT01336049Phase 2
• Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical TrialStatus unknownNCT01051765Phase 2